Abstract 1572P
Background
The identification of CLDN18.2, HER2, and PD-L1 as targetable biomarkers has contributed to defining different molecular subsets of gastroesophageal adenocarcinoma (GEA) and developing tailored treatments in the unresectable space. However, the prevalence and significance of their co-expression in the resectable stages remain unclear.
Methods
We evaluated CLDN18.2, HER2 and PD-L1 in a cohort of resectable GEA with paired clinical and WGS data. CLDN18.2 (ab222512, Abcam), HER2 (ab16662, Abcam) and PD-L1 (E1L3N, Cell Signaling) were assessed by immunohistochemistry (IHC) on adjacent slides from FFPE tumor samples. Positivity was defined as 2+/3+ staining in ≥40% of tumor cells for CLDN18.2, in ≥10% (surgical samples) or any percentage of tumor cells (biopsies) for HER2, and as a combined positive score (CPS)≥1 for PD-L1. Tumor mutational burden (TMB) was calculated as the number of non-synonymous somatic mutations per mega-base from WGS. Fisher’s exact test or Mann-Whitney test was used to compare baseline characteristics and log-rank test to compare survival curves, with statistical significance set at p=0.05 (two-sided).
Results
Eighty-four patients with resected GEA (71% GEJC/20% GC; 77% after neoadjuvant chemotherapy) were evaluated. CLDN18.2 was overexpressed in 18%, HER2 in 19%, and PD-L1 in 31% of the cases. Clinicopathological characteristics and OS were similar across subgroups (all p>0.05), except for significantly more stage III disease at diagnosis in HER2+ve (OR 6.07, p=0.02) and PD-L1+ve (OR 7.91, p<0.01) compared to their negative counterpart. Among CLDN18.2+ve cases, 4 patients (27%) co-expressed HER2 and 6 (40%) PD-L1. CLDN18.2+ve/HER2+ve cases were all MSS, mostly PD-L1-ve (n=3/4), and their TMB was significantly higher compared to CLDN18.2+ve only (10.46 vs 5.62, p=002). TMB was not significantly different by PD-L1 status in the CLDN18.2+ve subgroup nor between CLDN18.2+ve and HER2+ve subgroups, taking co-expressors out.
Conclusions
Biomarker co-expression may be frequent in the CDLN18.2+ve subset, and CLDN18.2+ve/HER2+ve may reveal a genomically more complex subgroup. Evaluation in larger datasets is required to understand its biological significance and potential therapeutic implications.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
L. Rimassa: Financial Interests, Personal, Advisory Board, Consulting and advisory role: AstraZeneca, Basilea, Bayer, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho, Zymeworks; Financial Interests, Personal, Invited Speaker, Lecture fees: AstraZeneca, Incyte, Roche, Servier; Financial Interests, Personal, Other, Travel expenses: AstraZeneca; Financial Interests, Institutional, Steering Committee Member: Exelixis, Incyte, Ipsen, Nerviano Medical Sciences, Roche; Financial Interests, Institutional, Coordinating PI, National (Italian) coordinating PI: AstraZeneca, BeiGene; Financial Interests, Institutional, Local PI: Agios, Eisai, FibroGen, Lilly, MSD, Zymeworks; Financial Interests, Institutional, Funding: Ipsen. R.C. Fitzgerald: Financial Interests, Personal, Advisory Board, Invited speaker and expert advisor: Medtronic; Financial Interests, Personal, Stocks/Shares, Shareholder in startup: Cyted Ltd; Financial Interests, Institutional, Advisory Board, Licensing fees for technology development and associated patents: Medtronic; Financial Interests, Personal, Other, Founder shares: Cyted Ltd; Non-Financial Interests, Leadership Role, Advisory: Cyted Ltd. E. Smyth: Financial Interests, Personal, Invited Speaker: Amgen, Bristol Myers Squibb, Imedex, Merck, Novartis, Prova Education, Servier, TouchIME, Elsevier, PeerVoice, Cor2Ed, Daiichi Sankyo; Financial Interests, Personal, Other, TSC: Amgen; Financial Interests, Personal, Advisory Board: Astellas, AstraZeneca, Bristol Myers Squibb, Bristol Myers Squibb, My Personal Therapeutics, Novartis, Roche, Servier, Zymeworks, Viracta; Financial Interests, Personal, Other, IDMC: BeiGene, Zymeworks; Financial Interests, Personal, Other, IDMC chair: Everest Clinical Research; Financial Interests, Personal, Officer: EORTC GI Clinical Trials Group; Financial Interests, Institutional, Local PI: Daiichi Sankyo, Merus, Basilea, MSD, Mirati; Financial Interests, Institutional, Coordinating PI: Roche, AstraZeneca, Amgen; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb; Non-Financial Interests, Leadership Role, Trustee: UK & Ireland Oesophagogastric Group (UKIOG). All other authors have declared no conflicts of interest.
Resources from the same session
1590P - Real-world gastric cancer (GC) in Latin America (LATAM) and Europe (EU)
Presenter: Berenice Freile
Session: Poster session 22
1591P - Gastric cancer in young patients under 40 years: 5-year analyses of Georgian cancer registry
Presenter: Tamar Esakia
Session: Poster session 22
1617P - PRODIGE 29-UCGI 26 (NEOPAN): Quality of life results of a phase III randomised trial comparing chemotherapy with folfirinox (FFX) or gemcitabine (gem) in locally advanced pancreatic carcinoma (LAPC)
Presenter: Michel Ducreux
Session: Poster session 22
1618P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
Presenter: Alison Schram
Session: Poster session 22
1620P - A phase II study of perioperative nalirifox in patients with resectable pancreatic ductal adenocarcinoma (rPDAC): Survival update and biomarkers analysis of the NITRO trial
Presenter: Davide Melisi
Session: Poster session 22
1621P - Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: Single-arm RAGNAR trial
Presenter: Shubham Pant
Session: Poster session 22
1622P - D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (pca)
Presenter: Shunsuke Kondo
Session: Poster session 22
1623P - Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: Results from the GOBLET study
Presenter: Dirk Arnold
Session: Poster session 22
1624P - Predictive factors for treatment success of second-line Nal-IRI/5-FU/FA in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) (AIO-PAK-0216)
Presenter: Manfred Lutz
Session: Poster session 22